La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aptorum Gr a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aptorum Gr..

Aptorum Gr (NASDAQ:APM) Azioni, Catena delle Opzioni

Aptorum Gr

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

apM Coin

MORIEN RESOURCES CORP ORD by Morien Resources Corp.

Morien Resources Corp

EAGLE GRAPHITE INC by Eagle Graphite Inc.

APM HUMAN SVCS INTL PTY by APM HUMAN SVCS INTL PTY LTD.

ApartmentLove Inc

ASPERMONT LTD by ASPERMONT LTD.

Amper SA

Aperam SA

Trust for Professional Managers ActivePassive Intermediate Municipal Bond ETF

President-elect Donald Trump has announced plans to impose a 25% tariff on all products from Mexico and Canada in response to the ongoing border crisis, stirring economic concerns.
What Happened: Trump took to Truth Social on Monday, to express his concern over the increasing number of people crossing the borders from Mexico and Canada into the United States. He described the situation as an &#8220;invasion&#8221; and blamed it for rising crime and drug levels.
Trump stated that he would sign an executive order on the first day of his administration to impose a 25% tariff on all products entering the U.S. from Mexico and Canada. He added that the tariff would remain in effect until the drug and illegal immigration issues are resolved. &#8220;Both Mexico and Canada have the absolute right and power to easily solve this long simmering problem. We hereby demand that they use this power, and until such time that they do, it is time for them to pay a very big price!&#8221; Trump criticized China for failing to curb the flow of fentanyl into the U.S. despite promises of harsh penalties for drug dealers. He claimed the drugs, largely entering through Mexico, are at unprecedented levels, announcing a 10% tariff hike on Chinese imports, above any additional tariffs, until the issue is addressed. &#8220;Thank you for your attention to this matter,&#8221; he said in a separate post.
See Also: <a href="https://www.benzinga.com/general/health-care/24/11/42077935/trump-picks-dr-oz-who-says-seniors-should-give-medical-marijuana-a-try-to-lead-centers-for-medicare-and-medicaid-services?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services</a>
Why It Matters: Trump&#8217;s proposed tariffs have <a href="https://www.benzinga.com/government/regulations/24/11/42058282/trumps-tariffs-could-have-severe-consequences-for-us-defense-sector-beijing-adviser-warns">raised concerns</a> among economists and industry experts. Ding Yifan, a researcher at China&#8217;s State Council's Development Research Center, warned that such tariffs could significantly impact the U.S. economy, particularly the defense sector.
Moreover, a&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">Goldman Sachs economist</a>&nbsp;predicted that a universal tariff could push inflation back to 3%, complicating the Federal Reserve&#8217;s efforts to keep inflation at 2%.
Renowned economist Mohamed El-Erian also <a href="https://www.benzinga.com/government/regulations/24/11/42058282/trumps-tariffs-could-have-severe-consequences-for-us-defense-sector-beijing-adviser-warns">cautioned against oversimplifying</a> Trump&#8217;s tariff strategies, emphasizing that the issue is complex and requires a nuanced analysis. While Trump&#8217;s tariff proposals are likely to hurt companies with international supply chains, others like those in the software or entertainment industry like Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) that don&#8217;t sell physical products are likely to <a href="https://www.benzinga.com/trading-ideas/24/11/42144357/5-stocks-to-buy-before-tariffs-kick-in">remain protected</a> from any negative impact. Companies that have reliable production units outside China are also likely to benefit, these include names like AutoZone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) and Hasbro Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>).
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

News

Politics

Economics

General

NFLX

Trump Says He Will Impose 25% Tariffs On Canada, Mexico On First Day Of Office And Extra Tariffs On China Until They 'Pay Attention'

STOCK CLIMBS OVER 7% AT ITS HIGH, SIGNAL OCCURS AFTER EARLY WEAKNESS IN COIN
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="864" height="709" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25210401/Screen-Shot-2024-11-25-at-4.08.18-PM.png" alt="" class="wp-image-3606" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25210401/Screen-Shot-2024-11-25-at-4.08.18-PM.png 864w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25210401/Screen-Shot-2024-11-25-at-4.08.18-PM-300x246.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/25210401/Screen-Shot-2024-11-25-at-4.08.18-PM-768x630.png 768w" sizes="(max-width: 864px) 100vw, 864px" /></figure>
Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:01 AM on November 25th, a significant trading signal occurred for Coinbase Global , Inc. as it demonstrated a Power Inflow at a price of $294.76. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Coinbase&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Coinbase&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for COIN, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $294.76. The returns on the High price ($317.46) and Close price ($312.30) after the Power Inflow were respectively 7.5% and 6.0%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Signals

Markets

COIN

Tradepulse Power Inflow Alert: Coinbase Global Inc. Climbs Over 20 Points After Signal

Bernard Looney, former CEO of oil and gas giant BP plc, said on Sunday he will join AI data center start-up, Prometheus Hyperscale, as the chairman of the <a href="https://www.prometheushyperscale.com/news/bernard-looney-appointed-chairman">board of directors. </a>
The Details: Looney resigned from his position at BP last year after an investigation <a href="https://www.theguardian.com/business/2023/sep/12/bp-boss-bernard-looney-to-resign-after-failing-to-reveal-ties-with-colleagues">revealed</a> he had not properly disclosed previous relationships with colleagues before becoming CEO. Looney is taking his more than 30 years of experience in the energy industry to the Wyoming-based start-up Prometheus Hyperscale.&nbsp;
Looney told the New York Times in an interview he would be helping Prometheus attract AI hyperscalers such as Microsoft and Google in need of power and space for data centers.&nbsp;
I'll be helping them with customers," he said. "I'll be helping them with investors. I'll be helping them with strategy."
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Prometheus plans to build a $10 billion flagship data center in Evanston, Wyoming, which will be among the largest facilities of its kind in the world when completed — the company estimates in 2025 or 2026. The company says the project encompasses a 12,000-acre ranch, including a dedicated 640-acre plot for data center facilities. 
The company secured an initial 120 MW of grid power through Rocky Mountain Power, with plans for an additional 120 MW, as well as a <a href="https://www.prometheushyperscale.com/news/oklo-partners-with-wyoming-hyperscale-to-deliver-100-megawatts-to-its-data-centers">strategic partnership</a> with Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) a small-scale nuclear reactor company.
Prometheus signed a non-binding letter of intent with Oklo in May, outlining its intent to enter into a 20-year Power Purchase Agreement.&nbsp;
"As the widespread adoption of artificial intelligence increases, Oklo remains dedicated to providing clean, reliable and affordable energy solutions to meet the needs of our data center partners. Our partnership with Wyoming Hyperscale underscores our commitment to advancing sustainable energy practices and supporting high-efficiency operations within the data center industry," Jacob DeWitte, CEO of Oklo, said in the announcement in May.&nbsp;
Combining the partnership with Oklo and its plans for incorporating a mix of wind, solar and gas power sources, Prometheus has an on-site generation goal of over 1 GW.&nbsp;
Looney said in the interview that he aims to help Prometheus Hyperscale address what he called downsides of A.I., including potential in emissions.&nbsp;
"We have to work on that," he said.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Photo: Courtesy of Prometheus Hyperscale

Management

Tech

OKLO

Former BP Oil CEO Joins AI Data Center Startup Prometheus Hyperscale

Scotiabank analyst Nicholas Yulico maintains Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) with a Sector Outperform and raises the price target from $133 to $142.

Price Target

Analyst Ratings

WELL

Scotiabank Maintains Sector Outperform on Welltower, Raises Price Target to $142

Scotiabank analyst Tanya Jakusconek maintains Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) with a Sector Outperform and lowers the price target from $24 to $23.

GOLD

Scotiabank Maintains Sector Outperform on Barrick Gold, Lowers Price Target to $23

Scotiabank analyst Greg Harrison maintains BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) with a Sector Outperform and raises the price target from $45 to $48.

BBIO

Scotiabank Maintains Sector Outperform on BridgeBio Pharma, Raises Price Target to $48

Scotiabank analyst Eric Winmill maintains Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) with a Sector Outperform and lowers the price target from $2.5 to $2.25.

GROY

Scotiabank Maintains Sector Outperform on Gold Royalty, Lowers Price Target to $2.25

Scotiabank analyst Ben Isaacson maintains Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) with a Sector Outperform and lowers the price target from $60 to $50.

Scotiabank Maintains Sector Outperform on Sociedad Quimica Y Minera, Lowers Price Target to $50

Formula 1 is expanding with an 11th team joining the global motorsport for the 2026 season, naming General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) <a href="https://www.benzinga.com/24/11/42135392/general-motors-gears-up-for-potential-f1-entry-in-2026-report">with Andretti Global.</a>
While the new team is still over a year away from starting, it will add an increased American presence to the sport and more competition for recent and four-time consecutive champion <a href="https://www.benzinga.com/general/education/21/12/24561188/max-verstappen-claims-his-first-f1-world-championship-5-things-you-might-not-know-about-the-for">Max Verstappen.</a>
What Happened: Formula 1, which is a unit of publicly traded Liberty Formula One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONA#NASDAQ">FWONA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWONK#NASDAQ">FWONK</a>), announced it reached an agreement with General Motors for a new team, branded as Cadillac, which will enter beginning in 2026, following up a previous rejection of a GM-linked team <a href="https://www.benzinga.com/general/entertainment/24/01/36875148/formula-one-rejects-andretti-general-motors-team-bid-what-this-could-mean-for-us-growth-esp">earlier this year.</a>
General Motors will also become an engine supplier for the league at a later date, the league <a href="https://www.formula1.com/en/latest/article/statement-on-general-motors-application-to-join-fia-formula-one-world.69uoRF1uwHwXkr4efkpnhc">announced</a>. The GM team will use Ferrari engines until the GM engines are officially approved for the sport.
"With Formula 1's continued growth plans in the U.S., we have always believed that welcoming an impressive U.S. brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport," Liberty Media CEO Greg Maffei said.
General Motors President Mark Reuss called Formula 1 the "pinnacle of motorsports" and said the announcement of becoming the 11th team is an honor for the automotive company.
"We're committed to competing with passion and integrity to elevate the sport for race fans around the world," Reuss said. "This is a global stage for us to demonstrate GM's engineering expertise and technology leadership at an entirely new level."
The approval of the team comes after the U.S. Justice Department launched an investigation into why Liberty Media, who owns the commercial rights to Formula 1, would not approve the American team bid started by Michael Andretti.
The new team, called Cadillac F1, will be run by Andretti Global majority owners Dan Towriss and Mark Walter after Andretti stepped aside from the group in September. Former Formula 1 champion and racing legend Mario Andretti will have an ambassador role with Cadillac F1 while his son Michael will have no official position.
Read Also: <a href="https://www.benzinga.com/general/entertainment/23/12/36222143/netflix-lands-more-live-sports-how-success-of-docuseries-helped-pave-the-way">Netflix Lands More Live Sports: How Success Of Docuseries Helped Pave The Way</a>
Why It's Important: The announcement comes after Formula 1's Las Vegas Grand Prix, one of three U.S. races in 2024, was recently held and saw Max Verstappen <a href="https://www.espn.com/f1/story/_/id/42520866/max-verstappen-wins-fourth-f1-world-title-las-vegas-red-bull">win </a>his fourth consecutive Formula 1 World Championship.
While Verstappen finished fifth in the race, he secured enough points to guarantee that no one could match his points total with two races left in the season. This marks the fourth consecutive title by Verstappen with his first title in 2021 a close one with<a href="https://www.benzinga.com/general/sports/24/02/36897433/f1-legend-lewis-hamilton-set-to-join-ferrari-likely-to-replace-sainz-in-major-team-shake-up"> racing legend Lewis Hamilton.</a>
Verstappen has been dominant in the sport in recent years winning the title with races still left in season three of the four years. Verstappen won seven of the first 10 races this season before falling out of form but later did enough to win enough points to secure the title.
The new GM team marks the second American-owned team. Gene Haas owns a team but chooses to have international drivers. Michael Andretti's original vision was to have an American-owned team and also feature American drivers, something that fans of the sport will be closely watching.
Team expansion has been infrequent with four teams added in 2010 to push the total to 13 teams and 26 cars. Of the four teams added, one never raced and the other three were out of the league by 2017, as <a href="https://apnews.com/article/f1-grid-expansion-11th-team-andretti-9ffab2a3b1c71d59bd838b1c154b690f?taid=6744c0a5988d9800014d4a8b&amp;utm_campaign=TrueAnthem&amp;utm_medium=AP&amp;utm_source=Twitter">reported </a>by the Associated Press. &nbsp;
The existing 10 team owners have been against expansion due to the dilution of prize money, but have no formal say in the approval process.
Adding another American team could benefit ESPN, which is a unit of Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>). ESPN secured the renewal of the U.S. rights in 2022, paying an estimated $75 million to $90 million annually for the rights for three additional years.
ESPN fought off several other parties interested in the rights, as viewership for the sport has surged in recent years.
Along with recent growth in viewership in the U.S. Formula One teams have also experienced increased interest in ownership stakes from investors, including several notable American football players.
The Alpine racing team received&nbsp;<a href="https://www.formula1.com/en/latest/article.patrick-mahomes-travis-kelce-anthony-joshua-and-rory-mcilroy-among-host-of.3J4ua82zLZnEDJuM5Cegpe.html" target="_blank" rel="noreferrer noopener">investments&nbsp;</a>in 2023 from Kansas City Chiefs players&nbsp;Patrick Mahomes&nbsp;and&nbsp;Travis Kelce, professional golfer&nbsp;Rory McIlroy&nbsp;and actor&nbsp;Ryan Reynolds.
FWONA Price Action: Liberty Formula One shares were up 4.25% to $80.74 on Monday, hitting an intraday high of $80.88, which is a new 52-week high. The stock is up 41% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/09/41099414/ryan-reynolds-has-built-multiple-billion-dollar-brands-will-marketing-company-named-after-d">Ryan Reynolds&#8217; Billion-Dollar Streak: Will His Viral Marketing Firm Go Public Next?</a></li>
</ul>
Photo: Jay Hirano Photography via Shutterstock

Sports

Movers

Trading Ideas

FWONA

FWONK

Formula 1 Stock Hits 52-Week High, Announces 11th Team With General Motors/Andretti Global After Max Verstappen's Fourth Straight Title

SNBR

Sleep Number Issues Response To Public Letter To Shareholders From Stadium Capital Management; Reiterates That Its Highest Priority Is Identifying And Recruiting Optimal CEO Candidate

Scotiabank analyst Meny Grauman maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Sector Outperform and raises the price target from C$112 to C$147.

TSX:BMO

Scotiabank Maintains Sector Outperform on Bank of Montreal, Raises Price Target to C$147

The Company expects the Restated Financial Statements to reflect the following approximate impacts: as of December 31, 2023, (i) an increase in assets of $190 million, (ii) an increase in accrued expenses and other liabilities of $783 million, and (iii) a decrease in retained earnings of $593 million.&nbsp;
For the years ended December 31, 2023 and 2022, pre-tax income would be reduced by approximately $190 million to $3,636 million and $77 million to $5,641 million, respectively. For the third quarter of 2024, pre-tax income would decrease by approximately $6 million to $1,282 million while pre-tax income for the nine months ended September 30, 2024 would increase by approximately $700 million to $4,462 million (as compared to the pre-tax income reported in the financial information with respect to the quarter ended September 30, 2024 in the exhibits furnished with the Company's Current Report on Form 8-K filed with the SEC on October 16, 2024).

Discover Financial Services Gets NYSE Notice Regarding Filing Of Form 10-Q; Plans To Restate Certain Prior Period Financial Statements

Scotiabank analyst Meny Grauman maintains Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) with a Sector Outperform and raises the price target from C$85 to C$108.

TSX:CM

Scotiabank Maintains Sector Outperform on Canadian Imperial Bank, Raises Price Target to C$108

Guidance

LexinFintech Says Cautious About Short-term Economic Outlook And Anticipate Recently Released Government Stimulus Measures Targeting Economic Recovery To Gradually Take Effect

Dividends

LexinFintech Board Approves Amended Dividend Payout Policy, Increasing Payout Ratio To 25% Of Net Profit Starting In 2025

Scotiabank analyst Meny Grauman maintains Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Sector Outperform and raises the price target from C$167 to C$197.

TSX:RY

Scotiabank Maintains Sector Outperform on Royal Bank of Canada, Raises Price Target to C$197

LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) reported quarterly earnings of $0.28 per share. The company reported $521.85 in sales this quarter. This is a 100.00 percent decrease over sales of $480.94 million the same period last year.

Earnings

LexinFintech Holdings Q3 2024 Adj EPS $0.28, Sales $521.85M

Scotiabank analyst Meny Grauman maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Sector Outperform and raises the price target from C$86 to C$98.

TSX:TD

Scotiabank Maintains Sector Outperform on Toronto-Dominion Bank, Raises Price Target to C$98

Flint, Michigan&#8217;s <a href="https://lightnupcannabis.com/">Light'N Up Cannabis Company</a> is helping local families in need celebrate Thanksgiving with its annual give away of 1,000 turkeys this past Saturday.
"Once you get something like this started, it takes on a life of its own and is more fun and more rewarding each year," said Light'N Up founder Kyle Cohee.
"We've been through some tough times here in Flint, and people deserve every single break we can provide," he said. "Giving them the central part of a Thanksgiving meal is our honor and our way of thanking the people of Flint for supporting our store."
The veteran-owned business set aside 300 of the 1,308 turkeys for Vet Life, a local nonprofit serving veterans. Another eight turkeys went to the North End Soup Kitchen and area churches to help others in need.
Country music artist and veteran advocate Stephen Cochran joined the event, adding to the day's community spirit.
See Also: <a href="https://www.benzinga.com/government/regulations/24/11/42173811/hemp-and-thanksgiving-from-the-mayflower-to-independence-the-crop-that-helped-build-a-nation">Hemp And Thanksgiving: From The Mayflower To Independence, The Crop That Helped Build A Nation</a>
<h3 class="wp-block-heading">Cannabis-Infused Thanksgiving In Arizona</h3>
Meanwhile, in Arizona, Mint Café, the state's first and only canna-kitchen, is putting a unique twist on Thanksgiving dinner. 
According to WDRB, the dispensary is offering a selection of cannabis-infused dishes, including THC-infused gravy, cranberry sauce, garlic herb butter and cornbread. For dessert, customers can choose between pumpkin and pecan pies, also infused with THC.
These special menu items will be available to adults 21 and older, providing an alternative way to enjoy a Thanksgiving feast.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41843473/how-to-microdose-cannabis-for-a-stress-free-holiday-season-tips-for-newcomers">How To Microdose Cannabis For Stress-Free Holiday Season: Tips For Newcomers</a></li>
</ul>
Photo Shutterstock

Cannabis

Restaurants

1,000 Free Turkeys Donated By Michigan Dispensary, Cannabis-Infused Thanksgiving Feasts In Arizona

Citigroup analyst Michael Griffin maintains CBRE Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) with a Buy and raises the price target from $130 to $160.

CBRE

Citigroup Maintains Buy on CBRE Group, Raises Price Target to $160

JAGX and GNPX among Health Care movers

XTIA, PSNL and LIDR among mid-day movers

Andean Precious Metals Corp (APM) has gained Wednesday morning, with the stock increasing 888.10% in pre-market trading to 8.3. APM's short-term technical score of 55 indicates that the stock has traded more bullishly over the last month than 55% of stocks on the market. In the Biotechnology industry, which ranks 100 out o

Andean Precious Metals Corp (APM) has risen 888.10% Wednesday In Premarket Trading

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The best <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. 



Regulatory hurdles make finding biotech stocks to buy challenging if you don&rsquo;t have the patience to wait it out.



But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That&rsquo;s why it&rsquo;s a good idea to at least consider biotech, and whether they have a spot in your portfolio.



Biotech stocks represent companies involved in the research, development and commercialization of biological-based products that are designed to improve health. These companies can include pharmaceuticals, biotechnology, medical devices, and healthcare services.



While the industry is challenging because of the regulatory approval process and keen competition, biotech stocks do have some significant advantages. 



For example, they are relatively immune to economic downturns. Even when the economy does poorly, people and insurance companies will spend money on monthly medications they need to improve their quality of life. 



As the population ages, healthcare spending for pharmaceuticals and other medical products will continue to increase.



We&rsquo;re using the Portfolio Grader to find the best biotech stocks to buy in today&rsquo;s market. Each of these stocks gets top grades.



<h2>Eli Lilly &amp; Co. (LLY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/lly_eli_lilly_1600-300x169.png" alt="Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals XI"><div>Source: Jonathan Weiss / Shutterstock.com</div></div>Weight loss drugs are one of the most popular trends in the biotech industry right now, with an estimated <a href="https://www.niddk.nih.gov/health-information/health-statistics/overweight-obesity">42% of the U.S. population</a> considered obese. That&rsquo;s why the first two companies on our list are top picks, both of them are soaring on the strength of their weight loss medications.



The U.S.-based company in this equation is Eli Lilly &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/lly-stock-quote/">LLY</a>), which markets its obesity drug under the name Zepbound. About 1 in 3 people who took the injectable drug at its highest dose (15 mg) report losing more than 58 pounds over a 72-week period.



The drug in Zepbound, tirzepatide, is also used in another highly successful Lilly product called Mounjaro, which is used to treat type 2 diabetes. Analysts believe that Zepbound can eventually be worth $25 billion a year in sales, and that Mounjaro sales could jump from $5.2 billion in 2023 to $16 billion in 2024.



<h2>Novo Nordisk (NVO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/nvo-stock-300x169.jpg" alt="Novo Nordisk logo on a corporate building"><div>Source: joreks / Shutterstock.com</div></div>The European entry into this equation is Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>), which has an injectable weight loss drug of its own called Wegovy. Wegovy was approved in 2021 in the U.S. to treat obesity and recently expanded to the U.K.



Expansion came with some growing pains, though. Some pharmacies continue to report shortages, and Novo Nordisk <a href="https://www.novonordisk-us.com/supply-update.html">says</a> its running its manufacturing lines 24 hours a day to try to maintain the supply.



Norvo Nordisk also manufactures the drug Ozempic as a treatment for type 2 diabetes, but doctors have also prescribed it as a treatment for weight loss.



NVO saw <a href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167013">revenue</a> of $21.4 billion in the fourth quarter, up 31% from the previous year. Profits of $7.7 billion were a 51% increase from the previous year.



NVO stock is up 20% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Corbus Pharmaceuticals (CRBP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/crbp1600-300x169.png" alt="Corbus Pharmaceuticals (CRBP) leads in developing innovative drugs to treat inflammatory and fibrotic diseases. Exceptional quality patient focus"><div>Source: MacroEcon / Shutterstock.com</div></div>Corbus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/crbp-stock-quote/">CRBP</a>) is a Massachusetts-based drugmaker specializing in oncology treatments. The company has potential drugs in its pipeline to treat solid tumors with antibody drug conjugates and monoclonal antibodies.



The most advanced treatment is treating U.S. patients with metastatic urothelial cancer <a href="https://www.corbuspharma.com/press-releases/detail/410/corbus-announces-dosing-of-first-patient-in-u-s-phase-1">in a trial study</a>.



Corbus also started work on a treatment for obesity and related conditions, although trials for that aren&rsquo;t expected to begin until the fourth quarter of this year.



Corbus doesn&rsquo;t have revenue coming in yet, so it&rsquo;s seeing steep losses &ndash; $8 million in the fourth quarter and $44.6 million for the full year. But that&rsquo;s expected for a biotech stock that has drugs in the pipeline but none yet for sale. You have to be willing to ride it out.



Many investors are. CRBP stock is up more than 500% so far this year as the market reacts to positive developments in the company&rsquo;s clinical trials. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Aptorum Group (APM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/09/apm-stock-1-300x169.jpg" alt="A magnifying glass zooms in on the website for Aptorum Group (APM)."><div>Source: Pavel Kapysh / Shutterstock.com</div></div>Aptorum Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/apm-stock-quote/">APM</a>) is a U.K.-based pharmaceutical company developing oncology and infectious diseases treatments. 



Its approach includes screening approved drug molecules and using its research platform to seek and develop new treatments and therapies.



The company recently agreed to a <a href="https://www.marketwatch.com/story/aptorum-group-to-merge-with-yoov-group-split-off-legacy-assets-28822b75">reverse merger</a> between its wholly owned subsidiary and YOOV Group, specializing in AI techniques to optimize business operations. &nbsp;APM shareholders will own 10% of the combined company after the merger.



Aptorum also plans to split off its legacy business assets into a subsidiary to be called Aptorum Therapeutics.



News of the merger and restructuring turbocharged APM shares, which are now up 264% in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Merck &amp; Co. (MRK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mrk-stock-3-300x169.jpg" alt="Merck (MRK) logo outside of corporate building"><div>Source: Atmosphere1 / Shutterstock.com</div></div>Merck &amp; Co. (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) is a New Jersey-based pharmaceutical company best known for its Keytruda cancer treatment. Keytruda brought in <a href="https://www.fiercepharma.com/pharma/whos-no-1-25b-sales-mercks-keytruda-appears-set-be-top-selling-drug-2023">$25 billion</a> in sales in 2023, making it the top-selling drug in the world.



But Merck also has many other drugs on the market, including Gardasil for human papillomavirus; ProQuad, which is a vaccine for measles, mumps, rubella and chickenpox; and Januvia for type 2 diabetes. And that&rsquo;s important, as Merck will lose exclusivity for Keytruda in 2028, making it available for generic substitutes.



Merck expanded that pipeline last month by <a href="https://www.merck.com/news/merck-completes-acquisition-of-harpoon-therapeutics-inc/">completing its acquisition</a> of Harpoon Therapeutics. The company&rsquo;s lead drug candidate treats small cell lung cancer and neuroendocrine tumors.



Earnings for the <a href="https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2023-financial-results/">fourth quarter</a> included revenue of $14.6 billion, up 6% from a year ago. The company reported a loss of $1.2 billion and 48 cents per share as part of previously announced charges incurred in its deal with Daiichi Sankyo to jointly develop three cancer treatments.



MRK stock is up 16% in 2024 and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Gyre Therapeutics (GYRE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Gyre Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/">GYRE</a>) is a North Carolina-based biotech company developing treatments for organ fibrosis and inflammatory diseases. 



The company completed a Phase 2 trial in China for its treatment of hepatitis B-induced liver fibrosis.



It&rsquo;s now planning a Phase 2 trial for the treatment in the U.S. The drug candidate, Hydronidone, is a structural analog of pirfenidone, which is already approved in the U.S. and China for the treatment of idiopathic pulmonary fibrosis.



The company says there are more than 140 million people who have liver fibrosis from hepatitis B, with no approved therapies on the market. So, its treatment has the potential to be profitable for investors.



Gyre posted full-year revenue in 2023 of $113.5 million, up from $102.3 million in 2022.



GYRE stock is up 330% in the last 12 months, but has been falling so far in 2024. It gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



<h2>Neurogene (NGNE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>Neurogene (NASDAQ:<a href="https://investorplace.com/stock-quotes/ngne-stock-quote/">NGNE</a>) is a biotech company that is developing what it calls EXACT gene therapy technology. 



The platform can be used to achieve optimized levels of transgene expression for each drug candidate, which Neurogene says gives it an advantage over traditional gene therapy.



It&rsquo;s currently working with the platform to develop its lead gene therapy candidate for Rett syndrome, which is a disorder seen in children that impairs their ability to walk, eat, speak or breathe.



The company went public just last year in a <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-announces-closing-merger-neoleukin-therapeutics-and">reverse merger</a> with cancer drug developer Neoleukin Therapeutics backed by investment firms that put $95 million into the newly formed company. The investment is expected to <a href="https://ir.neurogene.com/news-releases/news-release-details/neurogene-reports-fourth-quarter-and-full-year-2023-financial">assure Neurogene of funding</a> until the second half of 2026.



That gives it a solid window to develop and get approvals.



NGNE stock is up 95% this year and gets an &ldquo;A&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier held LLY and NVO. He did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



The InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/04/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024/">7 A-Rated Aggressive Biotech Stocks to Bet On in 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

CGC, GENE and HOLO among mid-day movers

Aptorum Group (APM) has released an update. Aptorum Group, a biopharmaceutical company, has reported a decreased net loss of $4.3 million for the f...

Aptorum Group Reports Decreased Annual Loss

Aptorum Group reports FY results

Aptorum Group (APM) has released an update. Aptorum Group Limited has announced an amendment to extend the term of its Merger Agreement with YOOV G...

Aptorum Group Extends Merger Agreement Term

Aptorum Group (APM) has released an update. Aptorum Group Limited announced the resignation of two directors, Dr. Mirko Scherer and Mr. Charles Bat...

Aptorum Group Board Sees Key Resignations

Aptorum Group (APM) has released an update. Aptorum Group has scheduled its 2024 Annual General Meeting for December 10 in Hong Kong, where shareho...

Aptorum Group Announces Key Shareholder Meeting

AILE

AISP

ALRN

ANGH

ANVS

APAC

AQST

BNTC

BPTH

CRBP

EDBL

FEMY

GENE

GNPX

GYRE

HOLO

ICLK

INLX

JAGX

LFCR

LIDR

MIGI

NGNE

NRXP

PSNL

RETO

RLMD

SINT

SWVL

TFFP

THCH

TOON

TRUG

TSHA

WISA

WORX

WULF

XPON

XTIA

XTLB

Press Releases

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business

Comments

Aptorum Gr

Aptorum Gr (APM) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO